Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer

This publication has 9 references indexed in Scilit:

• High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer.
  Journal of Clinical Oncology, 1997
• Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
  Journal of Clinical Oncology, 1996
• Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.
  The Journal of Experimental Medicine, 1995
• Cytoplasmic c‐erbB‐2 protein expression correlates with survival in Dukes' B colorectal carcinoma
  Histopathology, 1994
• HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.
  Journal of Clinical Oncology, 1992
• Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease
  American Journal of Obstetrics and Gynecology, 1991
• Expression of the p185 encoded by her2 oncogene in normal and transformed human tissues
  International Journal of Cancer, 1990
• Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
  Science, 1987
• The Spread of Rectal Cancer and its Effect on Prognosis
  British Journal of Cancer, 1958